Accrued expenses consisted of the following (in thousands):
June 30,
December 31,
2022
2021
Accrued research and development costs
$
6,756
3,893
Accrued clinical trial costs
2,853
1,025
Other accrued liabilities
1,800
2,529
Accrued related party liabilities
74
175
Total accrued expenses
11,483
7,622
Tabular disclosure of the components of accrued liabilities.
No definition available.
Consolidated balance sheet.